Literature DB >> 1371306

Clonal deletion of postthymic T cells: veto cells kill precursor cytotoxic T lymphocytes.

K Hiruma1, H Nakamura, P A Henkart, R E Gress.   

Abstract

Veto cell-mediated suppression of cytotoxic T lymphocyte (CTL) responses has been proposed as one mechanism by which self-tolerance is maintained in mature T cell populations. We have previously reported that murine bone marrow cells cultured in the presence of high-dose interleukin 2 (IL-2) (activated bone marrow cells [ABM]) mediate strong veto suppressor function. To examine mechanisms by which ABM may suppress precursor CTL (p-CTL) responses, we used p-CTL generated from spleen cells of transgenic mice expressing a T cell receptor specific for H-2 Ld. It was demonstrated that the cytotoxic response by these p-CTL after stimulation with irradiated H-2d/k spleen cells was suppressed by DBA/2 (H-2d) ABM, but not by B10.BR (H-2k) ABM or dm1 (Dd, Ld mutant) ABM. Flow cytometry analysis with propidium iodide staining revealed that these p-CTL were specifically deleted by incubation with H-2d ABM, but not with H-2k ABM. These data indicate that ABM veto cells kill p-CTL with specificity for antigens expressed on the surface of the ABM, and that the mechanism for veto cell activity of ABM is clonal deletion of p-CTL.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371306      PMCID: PMC2119146          DOI: 10.1084/jem.175.3.863

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  A cell culture model for T lymphocyte clonal anergy.

Authors:  R H Schwartz
Journal:  Science       Date:  1990-06-15       Impact factor: 47.728

2.  Inhibition of the lysosomal pathway of protein degradation in isolated rat hepatocytes by ammonia, methylamine, chloroquine and leupeptin.

Authors:  P O Seglen; B Grinde; A E Solheim
Journal:  Eur J Biochem       Date:  1979-04-02

3.  The role of cytoplasmic granules in cytotoxicity by large granular lymphocytes and cytotoxic T lymphocytes.

Authors:  P Henkart; M Henkart; P Millard; P Frederikse; J Bluestone; R Blumenthal; C Yue; C Reynolds
Journal:  Adv Exp Med Biol       Date:  1985       Impact factor: 2.622

4.  Inhibition of NK and ADCC activity by antibodies against purified cytoplasmic granules from rat LGL tumors.

Authors:  C W Reynolds; D Reichardt; M Henkart; P Millard; P Henkart
Journal:  J Leukoc Biol       Date:  1987-12       Impact factor: 4.962

5.  Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes.

Authors:  P Kisielow; H Blüthmann; U D Staerz; M Steinmetz; H von Boehmer
Journal:  Nature       Date:  1988-06-23       Impact factor: 49.962

6.  Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.

Authors:  E Azuma; H Yamamoto; J Kaplan
Journal:  J Immunol       Date:  1989-09-01       Impact factor: 5.422

7.  Clonal anergy induced in mature V beta 6+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells.

Authors:  H G Rammensee; R Kroschewski; B Frangoulis
Journal:  Nature       Date:  1989-06-15       Impact factor: 49.962

8.  Cells in bone marrow and in T cell colonies grown from bone marrow can suppress generation of cytotoxic T lymphocytes directed against their self antigens.

Authors:  S Muraoka; R G Miller
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

9.  Intrathymic elimination of Mlsa-reactive (V beta 6+) cells during neonatal tolerance induction to Mlsa-encoded antigens.

Authors:  H R MacDonald; T Pedrazzini; R Schneider; J A Louis; R M Zinkernagel; H Hengartner
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

10.  Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance.

Authors:  Y Liu; C A Janeway
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Treatment of an autoimmune disease with "classical" T cell veto: a proposal.

Authors:  U D Staerz; Y Qi
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

2.  CTLs respond with activation and granule secretion when serving as targets for T-cell recognition.

Authors:  Oren Milstein; David Hagin; Assaf Lask; Shlomit Reich-Zeliger; Elias Shezen; Eran Ophir; Yaki Eidelstein; Ran Afik; Yaron E Antebi; Michael L Dustin; Yair Reisner
Journal:  Blood       Date:  2010-11-02       Impact factor: 22.113

3.  Prevention of graft rejection by donor type II CD8(+) T cells (Tc2 cells) is not sufficient to improve engraftment in fetal transplantation.

Authors:  Jeng-Chang Chen; Ming-Ling Chang; Hanmin Lee; Marcus O Muench
Journal:  Fetal Diagn Ther       Date:  2005 Jan-Feb       Impact factor: 2.587

Review 4.  Immune tolerance and transplantation.

Authors:  Onder Alpdogan; Marcel R M van den Brink
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

5.  Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway.

Authors:  Jacopo Mariotti; Jason Foley; Kaitlyn Ryan; Nicole Buxhoeveden; Veena Kapoor; Shoba Amarnath; Daniel H Fowler
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

6.  AKR.H-2b lymphocytes inhibit the secondary in vitro cytotoxic T-lymphocyte response of primed responder cells to AKR/Gross murine leukemia virus-induced tumor cell stimulation.

Authors:  R F Rich; W R Green
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Hematopoietic stem cell transplantation across major genetic barriers.

Authors:  Yair Reisner
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

8.  The surprising kinetics of the T cell response to live antigenic cells.

Authors:  Aaron J Tyznik; Michael J Bevan
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

9.  Hybrid antibody mediated veto of cytotoxic T lymphocyte responses.

Authors:  Y Qi; R Berg; M A Singleton; J E Debrick; U D Staerz
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.